Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 7/20 | 0.69 |
| ▸ | CHRNA4 | P43681 | 7/20 | 0.69 |
| ▸ | CHRNB4 | P30926 | 4/20 | 0.69 |
| ▸ | CHRNA3 | P32297 | 4/20 | 0.69 |
| ▸ | CHRNA7 | P36544 | 3/20 | 0.69 |
| ▸ | BRD4 | O60885 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL52844 | 1.00 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL25021936 | 1.00 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL30306973 | 1.00 | CHRNB2 (0.69) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL4913359 | 0.92 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL57209 | 0.92 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| SCHEMBL1161371 | 0.90 | — | — | |
| Hydrochloric Acid SCHEMBL8103687 | 0.90 | CHRNB2 (0.58) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL27653360 | 0.88 | CHRNB2 (0.65) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 | |
| Hydrochloric Acid SCHEMBL364708 | 0.88 | — | — | |
| SCHEMBL5220409 | 0.87 | CHRNB2 (0.60) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | BAESCHLIN DANIEL KASPAR | 2008-08-14 | — | — | US | disclosed |
| EP-1879882-A1 | 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | Novartis AG (CH) | 2008-01-23 | — | — | EP | disclosed |
| WO-2006117183-A1 | 3 -M0N0- AND 3 , 5-DISUBSTITUTED PIPERIDINE DERIVATIVES AS RENIN INHIBITORS | NOVARTIS AG (CH) | 2006-11-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080194629-A1 | 3-Mono-and 3,5-Disubstituted Piperidine Derivatives as Renin Inhibitors | REN, ACE, AGTR1 | CHRNB2 4570/4885CHRNA4 3794/4885CHRNB4 4283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.